Avid Bioservices Reports Financial Results for Second Quarter Fiscal 2019 and Recent Developments
-- Fiscal 2019 Projected Revenue of
-- Signed Project Expansion Orders for
-- Successfully Executed Scheduled Broad Scale Facilities Maintenance and Upgrade Program --
Highlights Since
“During the second quarter we have made very significant progress in both the commercial arena and in our operations as we continue to execute to plan. Re-launching the company as a dedicated biologics contract development and manufacturing organization is a challenging endeavor and I am exceptionally pleased with our progress,” said
“On the commercial front we continue to see strong demand and we are making substantial progress in advancing both new and existing projects and improving our profitability. We are engaged in negotiations on new programs that will contribute revenue both during the current fiscal year and through fiscal year 2020 and, perhaps more importantly, many of our current customer programs expanded during the quarter. In addition to securing nearer-term business, our recently installed and highly experienced business development team is advancing longer lead time discussions with established biopharmaceutical clients for future commercial opportunities.
“To support the on-boarding of new projects and to deliver robust, compliant and cost-effective processes to our expanding and diversifying customer base, we continue to strengthen our process development function via the expansion and enhancement of our laboratories and the addition of state-of-the-art equipment. Process development services will become an increasingly important contributor to revenue and will build a strong pipeline of future manufacturing opportunities.
“It’s pleasing to be able to report revenue of over
“Collectively our significant operational and commercial progress, along with diligent management of our financial resources position
Recent Developments
- Signed project expansion orders with current clients representing future revenue in the amount of
$6.3 million during the second quarter.
- Increased marketing and media activities during the quarter to enhance industry visibility. Received double the number of Requests for Proposal in Q2 2019 as compared to Q1 2019 and increased the number of proposals issued by 100% during the same period.
- Sold remaining legacy R&D asset, r84, to
Oncologie, Inc. , for$1.0 million upfront. r84 is a pre-clinical novel therapeutic antibody asset targeting VEG-F that has demonstrated anti-tumor activity in animal models. Under the terms of the purchase and assignment agreement, Avid is eligible to receive up to an additional$21.0 million in development, regulatory and commercialization milestones, as well as low to mid-single digit royalties on net sales upon commercialization of products utilizing r84.
- Continued progress with ongoing expansion and optimization of our process development capabilities and laboratory space, including:
- Expanding the total available process development laboratory space to more than 6,000 square feet;
- Upgrading the infrastructure and equipment within the existing process development laboratories;
- Implementing new state-of-the-art technologies and equipment designed to facilitate efficient, high-throughput development of upstream and downstream manufacturing processes.
- Expanding the total available process development laboratory space to more than 6,000 square feet;
- Successfully executed the most comprehensive sequential maintenance overhaul in the company’s history, to best serve our existing customers and entice new business.
Financial Highlights and Guidance
- The company is reaffirming revenue guidance for the full FY 2019 of $51 million - $55 million.
- The revenue backlog as of
October 31, 2018 was $36 million, the majority of which we expect to recognize in FY 2019.
- Contract manufacturing revenue from Avid's clinical and commercial biomanufacturing services was $10.2 million for the second quarter of FY 2019 compared to $12.8 million for the second quarter of FY 2018. The decline in the second quarter of FY 2019 was primarily due to decreased demand from our two lead customers as previously disclosed. In addition, our revenues were impacted by the scheduled facility maintenance and upgrade shutdown.
- Gross margin for the second quarter was a positive 3%, a significant improvement compared to a gross margin of negative 27% during the prior year period. The increase in gross margin for the quarter was primarily attributed to our product mix resulting in improved overhead efficiencies.
- Selling, general and administrative expenses for the second quarter of FY 2019 were $2.8 million, compared to $3.6 million for the second quarter of FY 2018. The decrease in the second quarter of FY 2019 was primarily due to reductions in facility costs and legal, accounting and other professional fees.
- For the second quarter of FY 2019, the company recorded consolidated net loss attributable to common stockholders of $2.9 million, or $0.05 per share, compared to a consolidated net loss attributable to common stockholders of $14.1 million, or $0.31 per share, for the second quarter of FY 2018.
- Avid reported $32.7 million in cash and cash equivalents as of October 31, 2018, compared to $42.3 million on April 30, 2018.
More detailed financial information and analysis may be found in Avid’s Quarterly Report on Form 10-Q, which will be filed with the
Conference Call
Avid will host a conference call and webcast this afternoon,
To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the
About
Avid Bioservices is a dedicated contract development and manufacturing organization (CDMO) focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides a comprehensive range of process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. With 25 years of experience producing monoclonal antibodies and recombinant proteins in batch, fed-batch and perfusion modes, Avid's services include cGMP clinical and commercial product manufacturing, purification, bulk packaging, stability testing and regulatory strategy, submission and support. The company also provides a variety of process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. www.avidbio.com
Forward-Looking Statements
Statements in this press release, which are not purely historical, including statements regarding Avid Bioservices' intentions, hopes, beliefs, expectations, representations, projections, plans or predictions of the future, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The forward-looking statements involve risks and uncertainties including, but not limited to, the risk the company may not achieve cash flow or EBITDA positive, the risk the company may experience delays in engaging new clients, the risk that the company may not be successful in executing client projects, the risk that the company may experience technical difficulties in completing client projects which could delay delivery of products to customers, revenue recognition and receipt of payment or the loss of the customer, the risk that one or more existing customers terminates its contract prior to completion or reduces or delays its demand for development or manufacturing services, and the risk that the company may need to use the majority of its cash to fund operations, thereby delaying the in-process upgrades to its process development capabilities and contemplated expansion plans. Our business could be affected by a number of other factors, including the risk factors listed from time to time in our reports filed with the Securities and Exchange Commission including, but not limited to, our annual report on Form 10-K for the fiscal year ended April 30, 2018, as well as any updates to these risk factors filed from time to time in our other filings with the Securities and Exchange Commission. We caution investors not to place undue reliance on the forward-looking statements contained in this press release, and we disclaim any obligation, and do not undertake, to update or revise any forward-looking statements in this press release except as may be required by law.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (UNAUDITED)
(in thousands, except share and per share information)
| Three Months Ended October 31, |
Six Months Ended October 31, |
||||||||||||||||
| 2018 | 2017 | 2018 | 2017 | ||||||||||||||
| Contract manufacturing revenue | $ | 10,178 | $ | 12,782 | $ | 22,767 | $ | 39,859 | |||||||||
| Cost of contract manufacturing | 9,844 | 16,242 | 21,241 | 36,690 | |||||||||||||
| Gross profit (loss) | 334 | (3,460 | ) | 1,526 | 3,169 | ||||||||||||
| Operating expenses: | |||||||||||||||||
| Selling, general and administrative | 2,816 | 3,596 | 6,031 | 7,449 | |||||||||||||
| Restructuring charges | — | 1,258 | — | 1,258 | |||||||||||||
| Total operating expenses | 2,816 | 4,854 | 6,031 | 8,707 | |||||||||||||
| Operating loss | (2,482 | ) | (8,314 | ) | (4,505 | ) | (5,538 | ) | |||||||||
| Interest and other income, net | 119 | 13 | 181 | 37 | |||||||||||||
| Loss from continuing operations before income taxes | $ | (2,363 | ) | $ | (8,301 | ) | $ | (4,324 | ) | $ | (5,501 | ) | |||||
| Income tax benefit | 173 | — | 173 | — | |||||||||||||
| Loss from continuing operations | $ | (2,190 | ) | $ | (8,301 | ) | $ | (4,151 | ) | $ | (5,501 | ||||||
| Income (loss) from discontinued operations, net of tax | 739 | (4,323 | ) | 739 | (8,328 | ) | |||||||||||
| Net loss | $ | (1,451 | ) | $ | (12,624 | ) | $ | (3,412 | ) | $ | (13,829 | ) | |||||
| Comprehensive loss | $ | (1,451 | ) | $ | (12,624 | ) | $ | (3,412 | ) | $ | (13,829 | ) | |||||
| Series E preferred stock accumulated dividends | (1,442 | ) | (1,442 | ) | (2,523 | ) | (2,523 | ) | |||||||||
| Net loss attributable to common stockholders | $ | (2,893 | ) | $ | (14,066 | ) | $ | (5,935 | ) | $ | (16,352 | ) | |||||
| Basic and diluted weighted average common shares outstanding | 56,008,541 | 45,097,474 | 55,889,325 | 44,935,600 | |||||||||||||
| Basic and diluted net (loss) income per common share attributable to common stockholders: | |||||||||||||||||
| Continuing operations | $ | (0.06 | ) | $ | (0.21 | ) | $ | (0.12 | ) | $ | (0.18 | ) | |||||
| Discontinued operations | $ | 0.01 | $ | (0.10 | ) | $ | 0.01 | $ | (0.18 | ) | |||||||
| Net loss per share attributable to common stockholders | $ | (0.05 | ) | $ | (0.31 | ) | $ | (0.11 | ) | $ | (0.36 | ) | |||||
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except share information)
| October 31, 2018 |
April 30, 2018 |
||||||
| Unaudited | |||||||
| ASSETS | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 32,694 | $ | 42,265 | |||
| Trade and other receivables | 4,197 | 3,754 | |||||
| Contract assets | 5,092 | — | |||||
| Inventories | 9,736 | 16,129 | |||||
| Prepaid expenses | 774 | 679 | |||||
| Assets of discontinued operations | — | 5,000 | |||||
| Total current assets | 52,493 | 67,827 | |||||
| Property and equipment, net | 26,279 | 26,479 | |||||
| Restricted cash | 1,150 | 1,150 | |||||
| Other assets | 302 | 304 | |||||
| Total assets | $ | 80,224 | $ | 95,760 | |||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 3,223 | $ | 1,909 | |||
| Accrued payroll and related costs | 1,829 | 2,564 | |||||
| Contract liabilities | 17,307 | 27,935 | |||||
| Other current liabilities | 433 | 905 | |||||
| Liabilities of discontinued operations | 416 | 4,550 | |||||
| Total current liabilities | 23,208 | 37,863 | |||||
| Deferred rent, less current portion | 2,126 | 2,159 | |||||
| Capital lease, less current portion | 93 | — | |||||
| Commitments and contingencies | |||||||
| Stockholders’ equity: | |||||||
| Preferred stock—$0.001 par value; 5,000,000 shares authorized; 1,647,760 shares issued and outstanding at October 31, 2018 and April 30, 2018, respectively | 2 | 2 | |||||
| Common stock—$0.001 par value; 150,000,000 shares authorized; 56,063,488 and 55,689,222 shares issued and outstanding at October 31, 2018 and April 30, 2018, respectively | 56 | 55 | |||||
| Additional paid-in capital | 614,541 | 614,810 | |||||
| Accumulated deficit | (559,802 | ) | (559,129 | ) | |||
| Total stockholders’ equity | 54,797 | 55,738 | |||||
| Total liabilities and stockholders’ equity | $ | 80,224 | $ | 95,760 | |||
Contacts:Stephanie Diaz (Investors)Vida Strategic Partners 415-675-7401 sdiaz@vidasp.comTim Brons (Media)Vida Strategic Partners 415-675-7402 tbrons@vidasp.com
Source: Avid Bioservices, Inc